200 related articles for article (PubMed ID: 11259564)
1. Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA.
Shimoyama M; Shimoyama N; Zhao GM; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2001 Apr; 297(1):364-71. PubMed ID: 11259564
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the binding of [3H][Dmt1]H-Dmt-D-Arg-Phe-Lys-NH2, a highly potent opioid peptide.
Neilan CL; Janvey AJ; Bolan E; Berezowska I; Nguyen TM; Schiller PW; Pasternak GW
J Pharmacol Exp Ther; 2003 Aug; 306(2):430-6. PubMed ID: 12663687
[TBL] [Abstract][Full Text] [Related]
3. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
4. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
[TBL] [Abstract][Full Text] [Related]
5. In vivo pharmacokinetics of selective mu-opioid peptide agonists.
Szeto HH; Lovelace JL; Fridland G; Soong Y; Fasolo J; Wu D; Desiderio DM; Schiller PW
J Pharmacol Exp Ther; 2001 Jul; 298(1):57-61. PubMed ID: 11408525
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the antinociceptive effects of intrathecal DALDA peptides following bolus intrathecal delivery.
Kokubu S; Eddinger KA; Nguyen TM; Huerta-Esquivel LL; Yamaguchi S; Schiller PW; Yaksh TL
Scand J Pain; 2019 Jan; 19(1):193-206. PubMed ID: 30367811
[TBL] [Abstract][Full Text] [Related]
7. Differential analgesic effects of a mu-opioid peptide, [Dmt(1)]DALDA, and morphine.
Shimoyama M; Szeto HH; Schiller PW; Tagaito Y; Tokairin H; Eun Cm; Shimoyama N
Pharmacology; 2009; 83(1):33-7. PubMed ID: 18987489
[TBL] [Abstract][Full Text] [Related]
8. Characterization of Analgesic Actions of the Chronic Intrathecal Infusion of H-Dmt-D-Arg-Phe-Lys-NH2 in Rat.
Kokubu S; Eddinger KA; Yamaguchi S; Huerta-Esquivel LL; Schiller PW; Yaksh TL
Neuromodulation; 2019 Oct; 22(7):781-789. PubMed ID: 30794333
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and bioactivity of monobiotinylated DALDA: a mu-specific opioid peptide designed for targeted brain delivery.
Bickel U; Yamada S; Pardridge WM
J Pharmacol Exp Ther; 1994 Feb; 268(2):791-6. PubMed ID: 8113991
[TBL] [Abstract][Full Text] [Related]
10. Transcellular transport of a highly polar 3+ net charge opioid tetrapeptide.
Zhao K; Luo G; Zhao GM; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Jan; 304(1):425-32. PubMed ID: 12490619
[TBL] [Abstract][Full Text] [Related]
11. [Dmt(1)]DALDA is highly selective and potent at mu opioid receptors, but is not cross-tolerant with systemic morphine.
Riba P; Ben Y; Nguyen TM; Furst S; Schiller PW; Lee NM
Curr Med Chem; 2002 Jan; 9(1):31-9. PubMed ID: 11860345
[TBL] [Abstract][Full Text] [Related]
12. Profound spinal tolerance after repeated exposure to a highly selective mu-opioid peptide agonist: role of delta-opioid receptors.
Zhao GM; Wu D; Soong Y; Shimoyama M; Berezowska I; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2002 Jul; 302(1):188-96. PubMed ID: 12065716
[TBL] [Abstract][Full Text] [Related]
13. Differential respiratory effects of [Dmt1]DALDA and morphine in mice.
Shimoyama M; Kuwaki T; Nakamura A; Fukuda Y; Shimoyama N; Schiller PW; Szeto HH
Eur J Pharmacol; 2005 Mar; 511(2-3):199-206. PubMed ID: 15792789
[TBL] [Abstract][Full Text] [Related]
14. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
15. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivities of mouse strains to morphine and [Dmt1]DALDA analgesia.
Neilan CL; King MA; Rossi G; Ansonoff M; Pintar JE; Schiller PW; Pasternak GW
Brain Res; 2003 Jun; 974(1-2):254-7. PubMed ID: 12742645
[TBL] [Abstract][Full Text] [Related]
17. Superior analgesic effect of H-Dmt-D-Arg-Phe-Lys-NH2 ([Dmt1]DALDA), a multifunctional opioid peptide, compared to morphine in a rat model of neuropathic pain.
Shimoyama M; Schiller PW; Shimoyama N; Toyama S; Szeto HH
Chem Biol Drug Des; 2012 Nov; 80(5):771-4. PubMed ID: 22834682
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of the dermorphin analog [Dmt(1)]DALDA, a highly potent and selective mu-opioid peptide.
Neilan CL; Nguyen TM; Schiller PW; Pasternak GW
Eur J Pharmacol; 2001 May; 419(1):15-23. PubMed ID: 11348625
[TBL] [Abstract][Full Text] [Related]
19. Tolerance develops in spinal cord, but not in brain with chronic [Dmt1]DALDA treatment.
Ben Y; Smith AP; Schiller PW; Lee NM
Br J Pharmacol; 2004 Dec; 143(8):987-93. PubMed ID: 15557286
[TBL] [Abstract][Full Text] [Related]
20. Blocking mu opioid receptors in the spinal cord prevents the analgesic action by subsequent systemic opioids.
Chen SR; Pan HL
Brain Res; 2006 Apr; 1081(1):119-25. PubMed ID: 16499888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
